PQQ (pyrroloquinoline quinone)
Also called: pyrroloquinoline quinone, PQQ disodium salt
Pyrroloquinoline quinone, a water-soluble quinone compound first identified in 1979; supplements and trials use PQQ disodium salt. The ingredient assessed by EFSA is made by fermentation with the bacterium Hyphomicrobium denitrificans and purified to at least 99.0%.
- Category
- Other
- Forms
- Pyrroloquinoline quinone disodium salt
- Strongest evidence
- C Limited
- Reviewed
- 2026-10-30
Class 2 Moderately studied in people. Four randomized placebo-controlled trials of PQQ disodium salt alone were found (cognition 2016 and 2022, blood lipids 2015, endurance training 2020), each with 23-64 participants. No systematic review stating a trial count was found. [3]
Fact-checked 2026-10-30 · How this guide is made
Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.
What research has studied
Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.
CBrain, mood and sleep2 topics
CHeart and blood vessels1 topic
CMuscles and exercise1 topic
A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials
| Topic studied | Grade | What the evidence shows |
|---|---|---|
| Cognitive function in healthy middle-aged and older adults | C | A 12-week RCT (64 randomized, 58 completed; 21.5 mg/day PQQ disodium salt) reported better memory, attention and executive-function scores than placebo; no adverse events were observed. [3] |
| Attention in healthy elderly people | C | A 12-week RCT in 41 elderly subjects (20 mg/day) found a smaller change in Stroop interference ratio with PQQ than placebo; visual-spatial scores rose only in a low-scoring subgroup. [2] |
| Blood lipids | C | A 12-week RCT in 29 healthy adults (20 mg/day) found no change in triglycerides and a marginally significant fall in LDL cholesterol, significant only in those with high baseline LDL. [1] |
| Aerobic performance with endurance training | C | A 6-week RCT in 23 untrained men (20 mg/day) found no difference from placebo in aerobic performance after training, although PGC-1alpha protein rose with PQQ. [4] |
Main constituents: Pyrroloquinoline quinone (PQQ), a water-soluble quinone compound [1]
Amounts studied and limits
Amounts used in research, not dosing advice. Products differ in form and strength; a clinician can advise on an individual dose.
- Trials used about 20 mg/day (21.5 mg/day in one) PQQ disodium salt for 6-12 weeks. [3]
Upper limits
- EFSA (2017) concluded PQQ disodium salt is safe for use in food supplements for healthy adults, except pregnant and lactating women, at up to 20 mg/day; the margin of exposure was 344, based on a NOAEL of 100 mg/kg body weight per day in a 90-day oral toxicity study. [5]
Safety and side effects
- Liver (NIH LiverTox)Nothing found
No published information found in the sources checked.
Details and sources - Pregnancy and breastfeedingEFSA (2017): the intended use assessed as safe excludes pregnant and lactating women.
1 statement in the profile.
Details and sources - Interactions with medicinesNothing found
No published information found in the sources checked.
Details and sources - Cancer evaluations (IARC, NTP)None found
No IARC or NTP evaluation was found in the lists checked.
Details and sources - FDA new dietary ingredient notifications5 on FDA's list
FDA does not approve dietary supplements. Each entry is one party's filing.
Details and sources - Dose in official monographsNone found
No published information found in the sources checked.
Details and sources
- In a 12-week trial in 41 elderly people (20 mg/day), there were no abnormal blood or urinary findings and no adverse internal or physical examination findings. [2]
- EFSA: information on the absorption, distribution, metabolism and excretion of PQQ in animals and humans is limited; the proposed 20 mg/day is at least 250 times the estimated background intake from foods. [5]
Identity, quality and standardization
- EFSA: the assessed ingredient (BioPQQ) is produced by fermentation with Hyphomicrobium denitrificans CK-275 and purified to a minimum purity of 99.0%. [5]
Regulatory status
- EU: assessed as a novel food by EFSA (2017) for use in food supplements for healthy adults, excluding pregnant and lactating women. [5]
- US: under DSHEA, FDA does not have the authority to approve dietary supplements before they are marketed; firms are responsible for ensuring their products are not adulterated or misbranded. [6]
Safety, quality and supply profile
Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-30). If our sources do not answer a question, we say so.
Compounds responsible
Compounds the sources name as the main or characteristic actives.
- Pyrroloquinoline quinone (PQQ) Quinone compound [P6]
US status
What FDA's published records show. FDA does not approve dietary supplements.
- FDA's published NDI notification list has 5 entries naming pyrroloquinoline quinone or its disodium salt (earliest NDI 544 submitted 2008-06-03; most recent NDI 1013 submitted 2017-03-21). Each notification covers one firm's specific ingredient and conditions of use; the list does not state FDA's response. [P1]
Cancer evaluations (IARC and NTP)
Evaluations name the exact material tested, which may differ from a supplement.
Liver (NIH LiverTox)
- No published information found in the sources checked.
Interactions with medicines
- No published information found in the sources checked.
Alcohol
- No published information found in the sources checked.
Interactions with other herbs and supplements
- No published information found in the sources checked.
Adulteration and substitution
- No published information found in the sources checked.
What a certificate of analysis should cover
Tests a quality specification for this material would include, with the reason for each.
- Identity: at least one appropriate test or examination to verify the identity of each component that is a dietary ingredient (21 CFR 111.75(a)(1)(i)) — General Part 111 requirement for every dietary ingredient; FDA may exempt a firm only by granting a petition under 111.75(a)(1)(ii). [P4]
Supply and conservation
- No published information found in the sources checked.
Absorption in people
- EFSA (2017): information on the absorption, distribution, metabolism and excretion of PQQ in animals and humans is limited. [P5]
Formulations studied to change absorption
Human data only.
- No published information found in the sources checked.
Dose in official monographs
As the monograph states it, for its jurisdiction; not personal advice.
- No published information found in the sources checked.
Pregnancy and breastfeeding
- EFSA (2017): the intended use assessed as safe excludes pregnant and lactating women. [P5]
Sources for this profile
- FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
- IARC Monographs. List of Classifications (last update 2026-07-23; checked 2026-10-30), 2026-07-23. monographs.iarc.who.int
- National Toxicology Program. Technical Reports (TR series index, TR-001 to TR-606; checked 2026-10-30), 2026-10-30. ntp.niehs.nih.gov
- eCFR. 21 CFR 111.75, What must you do to determine whether specifications are met? (current text, retrieved 2026-10-30), 2026-10-30. ecfr.gov
- EFSA NDA Panel. Safety of pyrroloquinoline quinone disodium salt as a novel food pursuant to Regulation (EC) No 258/97. EFSA J 2017;15(11):e05058 (PMID 32625350), 2017-11-20. pubmed.ncbi.nlm.nih.gov
- Nakano M, et al. Effects of pyrroloquinoline quinone disodium salt intake on the serum cholesterol levels of healthy Japanese adults. J Nutr Sci Vitaminol 2015;61(3):233-40 (PMID 26226960), 2015. pubmed.ncbi.nlm.nih.gov
Sources
- Nakano M, et al. Effects of pyrroloquinoline quinone disodium salt intake on the serum cholesterol levels of healthy Japanese adults. J Nutr Sci Vitaminol 2015;61(3):233-40 (PMID 26226960), 2015. pubmed.ncbi.nlm.nih.gov
- Itoh Y, et al. Effect of the antioxidant supplement pyrroloquinoline quinone disodium salt (BioPQQ) on cognitive functions. Adv Exp Med Biol 2016;876:319-325 (PMID 26782228), 2016. pubmed.ncbi.nlm.nih.gov
- Shiojima Y, et al. Effect of dietary pyrroloquinoline quinone disodium salt on cognitive function in healthy volunteers: a randomized, double-blind, placebo-controlled, parallel-group study. J Am Nutr Assoc 2022;41(8):796-809 (PMID 34415830), 2021-08-20. pubmed.ncbi.nlm.nih.gov
- Hwang PS, et al. Effects of pyrroloquinoline quinone (PQQ) supplementation on aerobic exercise performance and indices of mitochondrial biogenesis in untrained men. J Am Coll Nutr 2020;39(6):547-556 (PMID 31860387), 2020-08. pubmed.ncbi.nlm.nih.gov
- EFSA NDA Panel. Safety of pyrroloquinoline quinone disodium salt as a novel food pursuant to Regulation (EC) No 258/97. EFSA J 2017;15(11):e05058 (PMID 32625350), 2017-11-20. pubmed.ncbi.nlm.nih.gov
- U.S. Food and Drug Administration. Questions and Answers on Dietary Supplements (Content current as of 08/27/2026), 2026-08-27. fda.gov
- A
- Consistent results from several randomized trials or a systematic review of them
- B
- Some positive randomized trials, but small, short, few or inconsistent
- C
- Limited human evidence: single small trials, observational data or mixed results
- D
- Laboratory or animal evidence only; not shown in people
- X
- Well-designed human trials found no meaningful effect
More in this category: Alpha-lipoic acid · Bee pollen · Beetroot juice (dietary nitrate) · Berberine · Beta-glucan (oat and barley) · Betaine (trimethylglycine) · Bromelain · Caffeine · All entries A–Z · How to judge a supplement
Health information notice
These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.
Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.
EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.